Document:

Exhibit 4.7

  

  

  

  
    THIS WARRANT AND THE SHARES ISSUABLE HEREUNDER HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR THE SECURITIES LAWS OF ANY STATE AND, EXCEPT AS SET FORTH IN SECTIONS 5.3 AND 5.4 BELOW, MAY NOT BE OFFERED, SOLD, PLEDGED OR OTHERWISE TRANSFERRED UNLESS AND UNTIL
      REGISTERED UNDER SAID ACT AND LAWS OR, IN THE OPINION OF LEGAL COUNSEL IN FORM AND SUBSTANCE SATISFACTORY TO THE COMPANY, SUCH OFFER, SALE, PLEDGE OR OTHER TRANSFER IS EXEMPT FROM SUCH REGISTRATION.

     

    WARRANT TO PURCHASE STOCK

     

    	
            Company:

          	
            CASTLE BIOSCIENCES, INC., a Delaware corporation

          
	
            Number of Shares:

          	
            [______] (Subject to Section 1.7)

          
	
            Type/Series of Stock:

          	
            Series F Preferred (Subject to Section 1.7)

          
	
            Warrant Price:

          	
            $[_____] per share (Subject to Section 1.7)

          
	
            Issue Date:

          	
            [_________________]

          
	
            Expiration Date:

          	
            [_________________]. See also Section 5.1(b).

          
	
            Credit Facility:

          	
            This Warrant to Purchase Stock (as modified, amended and/or restated from time to time, the “Warrant”) is issued in connection with that certain Loan and Security Agreement of even date herewith among [__________], as Lender and Collateral Agent, the Lenders from time to time
              party thereto, including [__________], and the Company (as modified, amended and/or restated from time to time, the “Loan Agreement”).

          

    

      THIS WARRANT CERTIFIES THAT, for good and valuable consideration, [__________] [“[_____]” and,] (together with any successor or
        permitted assignee or transferee of this Warrant or of any shares issued upon exercise hereof, “Holder”) is entitled to purchase the
        number of fully paid and non-assessable shares (the “Shares”) of the above-stated Type/Series of Stock (the “Class”) of the above-named company (the “Company”) at
        the above-stated Warrant Price, all as set forth above and as adjusted pursuant to Section 2 of this Warrant, subject to the provisions and upon the terms and conditions set forth in this Warrant.  [Reference is made to Section 5.4 of this Warrant
        whereby [__________] shall transfer this Warrant to its parent company, [__________]].

       

      SECTION 1.      EXERCISE.

       

      1.1          Method of Exercise.  Holder may at any time and from time to time exercise this Warrant, in whole or in part, by delivering to the Company the original
          of this Warrant together with a duly executed Notice of Exercise in substantially the form attached hereto as Appendix 1 and, unless Holder is exercising this Warrant pursuant to a cashless exercise set forth in Section 1.2, a check, wire
          transfer of same-day funds (to an account designated by the Company), or other form of payment acceptable to the Company for the aggregate Warrant Price for the Shares being purchased.

       

      1.2          Cashless Exercise. On any exercise of this Warrant, in lieu of payment of the aggregate Warrant Price in the manner as specified in Section 1.1 above,
          but otherwise in accordance with the requirements of Section 1.1, Holder may elect to receive Shares equal to the value of this Warrant, or portion hereof as to which this Warrant is being exercised. Thereupon, the Company shall issue to the
          Holder such number of fully paid and non-assessable Shares as are computed using the following formula:

       

      X = Y(A-B)/A

       

      where:

       

      
        	

              	X =	
                the number of Shares to be issued to the Holder;

              

      

       

      
        	

              	Y =	
                the number of Shares with respect to which this Warrant is being exercised (inclusive of the Shares surrendered to the Company in payment of the aggregate Warrant
                  Price);

              

      

      
        1

        
          
 

      

      
        	

              	A =	
                the Fair Market Value (as determined pursuant to Section 1.3 below) of one Share; and

              

      

       

      
        	

              	B =	
                the Warrant Price.

              

      

       

      1.3          Fair Market Value.  If the Company’s common stock is then traded or quoted on a nationally recognized securities exchange, inter-dealer quotation system
          or over-the-counter market (a “Trading Market”) and the Class is common stock, the fair market value of a Share shall be the closing
          price or last sale price of a share of common stock reported for the Business Day immediately before the date on which Holder delivers this Warrant together with its Notice of Exercise to the Company. If the Company’s common stock is then traded
          in a Trading Market and the Class is a series of the Company’s convertible preferred stock, the fair market value of a Share shall be the closing price or last sale price of a share of the Company’s common stock reported for the Business Day
          immediately before the date on which Holder delivers this Warrant together with its Notice of Exercise to the Company multiplied by the number of shares of the Company’s common stock into which a Share is then convertible. If the Company’s common
          stock is not traded in a Trading Market, the Board of Directors of the Company shall determine the fair market value of a Share in its reasonable good faith judgment.

       

      1.4          Delivery of Certificate and New Warrant.  Within a reasonable time after Holder exercises this Warrant in the manner set forth in Section 1.1 or 1.2
          above, the Company shall deliver to Holder a certificate representing the Shares issued to Holder upon such exercise and, if this Warrant has not been fully exercised and has not expired, a new warrant of like tenor representing the Shares not so
          acquired.

       

      1.5          Replacement of Warrant.  On receipt of evidence reasonably satisfactory to the Company of the loss, theft, destruction or mutilation of this Warrant
          and, in the case of loss, theft or destruction, on delivery of an indemnity agreement reasonably satisfactory in form, substance and amount to the Company or, in the case of mutilation, on surrender of this Warrant to the Company for
          cancellation, the Company shall, within a reasonable time, execute and deliver to Holder, in lieu of this Warrant, a new warrant of like tenor and amount.

       

      1.6          Treatment of Warrant Upon Acquisition of Company.

       

      (a)          Acquisition. For the purpose of this Warrant, “Acquisition”
          means any transaction or series of related transactions involving: (i) the sale, lease, exclusive license, or other disposition of all or substantially all of the assets of the Company (ii) any merger or consolidation of the Company into or with
          another person or entity (other than a merger or consolidation effected exclusively to change the Company’s domicile), or any other corporate reorganization, in which the stockholders of the Company in their capacity as such immediately prior to
          such merger, consolidation or reorganization, own less than a majority of the Company’s (or the surviving or successor entity’s) outstanding voting power immediately after such merger, consolidation or reorganization (or, if such Company
          stockholders beneficially own a majority of the outstanding voting power of the surviving or successor entity as of immediately after such merger, consolidation or reorganization, such surviving or successor entity is not the Company); or (iii)
          any sale or other transfer by the stockholders of the Company of shares representing at least a majority of the Company’s then-total outstanding combined voting power.

       

      (b)          Treatment of Warrant at Acquisition. In the event of an Acquisition in which the consideration to be received by the Company’s stockholders consists
          solely of cash, solely of Marketable Securities or a combination of cash and Marketable Securities (a “Cash/Public Acquisition”), either
          (i) Holder shall exercise this Warrant pursuant to Section 1.1 and/or 1.2 and such exercise will be deemed effective immediately prior to and contingent upon the consummation of such Acquisition or (ii) if Holder elects not to exercise the
          Warrant, this Warrant will expire immediately prior to the consummation of such Acquisition.

       

      (c)          The
          Company shall provide Holder with written notice of its request relating to the Cash/Public Acquisition (together with such reasonable information as Holder may reasonably require regarding the treatment of this Warrant in connection with such
          contemplated Cash/Public Acquisition giving rise to such notice), which is to be delivered to Holder not less than seven (7) Business Days prior to the closing of the proposed Cash/Public Acquisition. In the event the Company does not provide
          such notice, then if, immediately prior to the Cash/Public Acquisition, the fair market value of one Share (or other security issuable upon the exercise hereof) as determined in accordance with Section 1.3 above would be greater than the Warrant
          Price in effect on such date, then this Warrant shall automatically be deemed on and as of such date to be exercised pursuant to Section 1.2 above as to all Shares (or such other securities) for which it shall not previously have been exercised,
          and the Company shall promptly notify the Holder of the number of Shares (or such other securities) issued upon such exercise to the Holder and Holder shall be deemed to have restated each of the representations and warranties in Section 4 of the
          Warrant as the date thereof.

      
        2

        
          
 

      

      (d)          Upon the
          closing of any Acquisition other than a Cash/Public Acquisition defined above, the acquiring, surviving or successor entity shall assume the obligations of this Warrant, and this Warrant shall thereafter be exercisable for the same securities
          and/or other property as would have been paid for the Shares issuable upon exercise of the unexercised portion of this Warrant as if such Shares were outstanding on and as of the closing of such Acquisition, subject to further adjustment from
          time to time in accordance with the provisions of this Warrant.

       

      (e)          As used in
          this Warrant, “Marketable Securities” means securities meeting all of the following requirements: (i) the issuer thereof is then subject
          to the reporting requirements of Section 13 or Section 15(d) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”),
          and is then current in its filing of all required reports and other information under the Act and the Exchange Act; (ii) the class and series of shares or other security of the issuer that would be received by Holder in connection with the
          Acquisition were Holder to exercise this Warrant on or prior to the closing thereof is then traded in Trading Market, and (iii) following the closing of such Acquisition, Holder would not be restricted from publicly re-selling all of the issuer’s
          shares and/or other securities that would be received by Holder in such Acquisition were Holder to exercise or convert this Warrant in full on or prior to the closing of such Acquisition, except to the extent that any such restriction (x) arises
          solely under federal or state securities laws, rules or regulations, and (y) does not extend beyond six (6) months from the closing of such Acquisition.

       

      1.7          Adjustment to Class of Shares; Number of Shares; Warrant Price; Adjustments Cumulative. If, upon the closing of the Next Equity Financing, the Next
          Equity Financing Price shall be less than the Warrant Price in effect as of immediately prior thereto, then the “Class” shall be Next Equity Financing Securities from and after such closing, subject to adjustment thereafter from time to time in
          accordance with the provisions of this Warrant and the “Warrant Price” shall be the Next Equity Financing Price from and after such closing, subject to adjustment thereafter from time to time in accordance with the provisions of this Warrant;
          provided, that upon such date, if any, as the “Class” becomes Next Equity Financing Securities pursuant to this sentence, this Warrant
          shall be exercisable for such number of shares of such Class as shall equal (i) [_______] divided by (ii) the Next Equity Financing Price, subject to adjustment thereafter from time to time in accordance with the provisions of this Warrant. As
          used herein (i) “Next Equity Financing” means the first sale or issuance by the Company on or after the Issue Date of this Warrant set
          forth above, in a single transaction or series of related transactions, of shares of its convertible preferred stock or other senior equity securities to one or more investors for cash for financing purposes; (ii) “Next Equity Financing Securities” means the type, class and series of convertible preferred stock or other senior equity security sold or issued by the Company in
          the Next Equity Financing; and (iii) “Next Equity Financing Price” means the lowest price per share for which Next Equity Financing
          Securities are sold or issued by the Company in the Next Equity Financing.

       

      SECTION 2.      ADJUSTMENTS TO THE SHARES AND WARRANT PRICE.

       

      2.1          Stock Dividends, Splits, Etc. If the Company declares or pays a dividend or distribution on the outstanding shares of the Class payable in common stock
          or other securities or property (other than cash), then upon exercise of this Warrant, for each Share acquired, Holder shall receive, without additional cost to Holder, the total number and kind of securities and property which Holder would have
          received had Holder owned the Shares of record as of the date the dividend or distribution occurred. If the Company subdivides the outstanding shares of the Class by reclassification or otherwise into a greater number of shares, the number of
          Shares purchasable hereunder shall be proportionately increased and the Warrant Price shall be proportionately decreased. If the outstanding shares of the Class are combined or consolidated, by reclassification or otherwise, into a lesser number
          of shares, the Warrant Price shall be proportionately increased and the number of Shares shall be proportionately decreased.

      
        3

        
          
 

      

      2.2          Reclassification, Exchange, Combinations or Substitution. Upon any event whereby all of the outstanding shares of the Class are reclassified, exchanged,
          combined, substituted, or replaced for, into, with or by Company securities of a different class and/or series, then from and after the consummation of such event, this Warrant will be exercisable for the number, class and series of Company
          securities that Holder would have received had the Shares been outstanding on and as of the consummation of such event, and subject to further adjustment thereafter from time to time in accordance with the provisions of this Warrant. The
          provisions of this Section 2.2 shall similarly apply to successive reclassifications, exchanges, combinations substitutions, replacements or other similar events.

       

      2.3          Conversion of Preferred Stock. If the Class is a class and series of the Company’s convertible preferred stock, in the event that all outstanding shares
          of the Class are converted, automatically or by action of the holders thereof, into common stock pursuant to the provisions of the Company’s Certificate of Incorporation, including, without limitation, in connection with the Company’s initial,
          underwritten public offering and sale of its common stock pursuant to an effective registration statement under the Act (the “IPO”),
          then from and after the date on which all outstanding shares of the Class have been so converted, this Warrant shall be exercisable for such number of shares of common stock into which the Shares would have been converted had the Shares been
          outstanding on the date of such conversion, and the Warrant Price shall equal the Warrant Price in effect as of immediately prior to such conversion divided by the number of shares of common stock into which one Share would have been converted,
          all subject to further adjustment thereafter from time to time in accordance with the provisions of this Warrant.

       

      2.4          Adjustments for Diluting Issuances. Without duplication of any adjustment otherwise provided for in this Section 2, the number of shares of common stock
          issuable upon conversion of the Shares shall be subject to anti-dilution adjustment from time to time in the manner set forth in the Company’s Articles or Certificate of Incorporation as if the Shares were issued and outstanding on and as of the
          date of any such required adjustment.

       

      2.5          No Fractional Share. No fractional Share shall be issuable upon exercise of this Warrant and the number of Shares to be issued shall be rounded down to
          the nearest whole Share. If a fractional Share interest arises upon any exercise of the Warrant, the Company shall eliminate such fractional Share interest by paying Holder in cash the amount computed by multiplying the fractional interest by (i)
          the fair market value (as determined in accordance with Section 1.3 above) of a full Share, less (ii) the then-effective Warrant Price.

       

      2.6          Notice/Certificate as to Adjustments. Upon each adjustment of the Warrant Price, Class and/or number of Shares, the Company, at the Company’s expense,
          shall notify Holder in writing within a reasonable time setting forth the adjustments to the Warrant Price, Class and/or number of Shares and facts upon which such adjustment is based. The Company shall, upon written request from Holder, furnish
          Holder with a certificate of its Chief Financial Officer, including computations of such adjustment and the Warrant Price, Class and number of Shares in effect upon the date of such adjustment.

       

      SECTION 3.      REPRESENTATIONS AND COVENANTS OF THE COMPANY.

       

      3.1          Representations and Warranties. The Company represents and warrants to, and agrees with, the Holder as follows:

       

      (a)          The
          initial Warrant Price referenced on the first page of this Warrant is not greater than the price per share at which shares of the Class were last sold and issued prior to the Issue Date hereof in an arms-length transaction in which at least
          $500,000 of such shares were sold.

       

      (b)          All Shares
          which may be issued upon the exercise of this Warrant, and all securities, if any, issuable upon conversion of the Shares, shall, upon issuance, be duly authorized, validly issued, fully paid and non-assessable, and free of any liens and
          encumbrances except for restrictions on transfer provided for herein or under applicable federal and state securities laws. The Company covenants that it shall at all times cause to be reserved and kept available out of its authorized and
          unissued capital stock such number of shares of the Class, common stock and other securities as will be sufficient to permit the exercise in full of this Warrant and the conversion of the Shares into common stock or such other securities.

      
        4

        
          
 

      

      (c)          The
          Company’s capitalization table provided to Holder on the date hereof is true and complete, in all material respects, as of the Issue Date.

       

      3.2          Notice of Certain Events. If the Company proposes at any time to:

       

      (a)          declare
          any dividend or distribution upon the outstanding shares of the Class or common stock, whether in cash, property, stock, or other securities and whether or not a regular cash dividend;

       

      (b)         offer for
          subscription or sale pro rata to the holders of the outstanding shares of the Class any additional shares of any class or series of the Company’s stock (other than pursuant to contractual pre-emptive rights);

       

      (c)          effect any
          reclassification, exchange, combination, substitution, reorganization or recapitalization of the outstanding shares of the Class;

       

      (d)          effect an Acquisition or to liquidate, dissolve
          or wind up; or

       

      (e)          effect an IPO;

       

      then, in connection with each such event, the Company shall give Holder:

       

      (1)          at least
          seven (7) Business Days prior written notice of the date on which a record will be taken for such dividend, distribution, or subscription rights (and specifying the date on which the holders of outstanding shares of the Class will be entitled
          thereto) or for determining rights to vote, if any, in respect of the matters referred to in (a) and (b) above;

       

      (2)          in the
          case of the matters referred to in (c) and (d) above at least seven (7) Business Days prior written notice of the date when the same will take place (and specifying the date on which the holders of outstanding shares of the Class will be entitled
          to exchange their shares for the securities or other property deliverable upon the occurrence of such event); and

       

      (3)          with
          respect to the IPO, at least seven (7) Business Days prior written notice of the date on which the Company proposes to file its registration statement in connection therewith.

       

      Reference is made to Section 1.6(c) whereby this Warrant will be deemed to be exercised pursuant to Section 1.2 hereof if the Company does not give written
        notice to Holder of a Cash/Public Acquisition as required by the terms hereof. Company will also provide information requested by Holder that is reasonably necessary to enable Holder to comply with Holder’s accounting or reporting requirements.

       

      SECTION 4.      REPRESENTATIONS, WARRANTIES OF THE HOLDER.

       

      The Holder represents and warrants to the Company as follows:

       

      4.1          Purchase for Own Account. This Warrant and the securities to be acquired upon exercise of this Warrant by Holder are being acquired for investment for Holder’s account, not as a nominee or agent,
          and not with a view to the public resale or distribution within the meaning of the Act. Holder also represents that it has not been formed for the specific purpose of acquiring this Warrant or the Shares.

       

      4.2          Disclosure of Information.   Holder is aware of the Company’s business affairs and financial condition and has received or has had full access to all
          the information it considers necessary or appropriate to make an informed investment decision with respect to the acquisition of this Warrant and its underlying securities. Holder further has had an opportunity to ask questions and receive
          answers from the Company regarding the terms and conditions of the offering of this Warrant and its underlying securities and to obtain additional information (to the extent the Company possessed such information or could acquire it without
          unreasonable effort or expense) necessary to verify any information furnished to Holder or to which Holder has access.

      
        5

        
          
 

      

      4.3          Investment Experience. Holder understands that the purchase of this Warrant and its underlying securities involves substantial risk. Holder has
          experience as an investor in securities of companies in the development stage and acknowledges that Holder can bear the economic risk of such Holder’s investment in this Warrant and its underlying securities and has such knowledge and experience
          in financial or business matters that Holder is capable of evaluating the merits and risks of its investment in this Warrant and its underlying securities and/or has a preexisting personal or business relationship with the Company and certain of
          its officers, directors or controlling persons of a nature and duration that enables Holder to be aware of the character, business acumen and financial circumstances of such persons.

       

      4.4          Accredited Investor Status. Holder is an “accredited investor” within the meaning of Regulation D promulgated under the Act.

       

      4.5         The Act. Holder understands that this Warrant and the Shares issuable upon exercise hereof have not been registered under the Act in reliance upon a
          specific exemption therefrom, which exemption depends upon, among other things, the bona fide nature of the Holder’s investment intent as expressed herein. Holder understands that this Warrant and the Shares issued upon any exercise hereof must
          be held indefinitely unless subsequently registered under the Act and qualified under applicable state securities laws, or unless exemption from such registration and qualification are otherwise available. Holder is aware of the provisions of
          Rule 144 promulgated under the Act.

       

      4.6          Market Stand-off Agreement. If requested by the Company or an underwriter, Holder shall not sell or otherwise transfer, make any short sale of, grant
          any option for the purchase of, or enter into any hedging or similar transaction with the same economic effect as a sale of, any shares of the Company’s capital stock held by Holder (other than those included in the registration) during for such
          period of time as reasonably requested by the Company or such underwriter, but not to exceed the 180-day period following the effective date of a registration statement of the Company filed under the Securities Act of 1933, as amended (the “Lock Up Period”). Holder agrees to execute and deliver such other agreements as may be reasonably requested by the Company and/or the
          managing underwriter which are consistent with the foregoing or which are necessary to give further effect thereto. In order to enforce the foregoing covenant, the Company may impose stop-transfer instructions with respect to the shares of
          capital stock of the Company held by Holder until the end of such period. The underwriters of the Company’s stock are intended third party beneficiaries of this Section 4.6 and shall have the right, power and authority to enforce the provisions
          hereof as though they were a party hereto. Notwithstanding the foregoing, Holder shall only be subject to the foregoing provisions of this Section 4.6 so long as each of the Company’s other stockholders that hold at least 1% of the outstanding
          voting securities of the Company are subject to substantially the same requirements and restrictions.

       

      4.7          No Voting Rights. Holder, as a Holder of this Warrant, will not have any voting rights until the exercise of this Warrant.

       

      SECTION 5.      MISCELLANEOUS.

       

      5.1          Term; Automatic Cashless Exercise Upon Expiration.

       

      (a)          Term. Subject to the provisions of Section 1.6 above, this Warrant is exercisable in whole or in part at any time and from time to time on or before
          6:00 PM, Pacific time, on the Expiration Date and shall be void thereafter.

       

      (b)         Automatic Cashless Exercise upon Expiration. In the event that, upon the Expiration Date, the fair market value of one Share (or other security issuable
          upon the exercise hereof) as determined in accordance with Section 1.3 above is greater than the Warrant Price in effect on such date, then this Warrant shall automatically be deemed on and as of such date to be exercised pursuant to Section 1.2
          above as to all Shares (or such other securities) for which it shall not previously have been exercised, and the Company shall, within a reasonable time, deliver a certificate representing the Shares (or such other securities) issued upon such
          exercise to Holder.

      
        6

        
          
 

      

      5.2          Legends. Each certificate evidencing Shares (and each certificate evidencing the securities issued upon conversion of any Shares, if any) shall be
          imprinted with a legend in substantially the following form:

       

      THE SHARES EVIDENCED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE
        “ACT”), OR THE SECURITIES LAWS OF ANY STATE AND, EXCEPT AS SET FORTH IN THAT CERTAIN WARRANT TO PURCHASE STOCK ISSUED BY THE ISSUER TO
        [__________] DATED [______________], MAY NOT BE OFFERED, SOLD, PLEDGED OR OTHERWISE TRANSFERRED UNLESS AND UNTIL REGISTERED UNDER SAID ACT AND LAWS OR, IN THE OPINION OF LEGAL COUNSEL IN FORM AND SUBSTANCE SATISFACTORY TO THE ISSUER, SUCH OFFER,
        SALE, PLEDGE OR OTHER TRANSFER IS EXEMPT FROM SUCH REGISTRATION.

       

      5.3          Compliance with Securities Laws on Transfer. This Warrant and the Shares issued upon exercise of this Warrant (and the securities issuable, directly or
          indirectly, upon conversion of the Shares, if any) may not be transferred or assigned in whole or in part except in compliance with applicable federal and state securities laws by the transferor and the transferee (including, without limitation,
          the delivery of investment representation letters and legal opinions reasonably satisfactory to the Company, as reasonably requested by the Company). The Company shall not require Holder to provide an opinion of counsel if the transfer is to [an]
          [[__________] ([__________] parent company) or any other] affiliate of Holder, provided that any such transferee is an “accredited investor” as defined in Regulation D promulgated under the Act. Additionally, the Company shall also not require an
          opinion of counsel if there is no material question as to the availability of Rule 144 promulgated under the Act.

       

      5.4          Transfer Procedure. After receipt by [__________] of the executed Warrant, [__________] [may][will] transfer all [or part] of this Warrant to [its
          parent company, [__________]] [one or more of [__________]’s affiliates (each, an “[__________] Affiliate”), by execution of an
          Assignment substantially in the form of Appendix 2]. [By its acceptance of this Warrant, [__________] hereby makes to the Company each of the representations and warranties set forth in Section 4 hereof and agrees to be bound by all of the terms
          and conditions of this Warrant as if the original Holder hereof.] Subject to the provisions of [Article][Section] 5.3 and upon providing the Company with written notice, [__________] [[__________], any such [__________] Affiliate] and any
          subsequent Holder, may transfer all or part of this Warrant or the Shares issuable upon exercise of this Warrant (or the [securities] [Shares] issuable directly or indirectly, upon conversion of the Shares, if any) to any [other] transferee,
          provided, however, in connection with any such transfer, [__________] [the [__________] Affiliate(s)] or any subsequent Holder will give the Company notice of the portion of the Warrant being transferred with the name, address and taxpayer
          identification number of the transferee and Holder will surrender this Warrant to the Company for reissuance to the transferee(s) (and Holder if applicable); [and provided further, that any subsequent transferee other than [__________] shall
          agree in writing with the Company to be bound by all of the terms and conditions of this Warrant]. Notwithstanding any contrary provision herein, at all times prior to the IPO, Holder may not, without the Company’s prior written consent, transfer
          this Warrant or any portion hereof, or any Shares issued upon any exercise hereof, or any shares or other securities issued upon any conversion of any Shares issued upon any exercise hereof, to any person or entity who directly competes with the
          Company, except in connection with an Acquisition of the Company by such a direct competitor.

      
        7

        
          
 

      

      5.5          Notices. All notices and other communications hereunder from the Company to the Holder, or vice versa, shall be deemed delivered and effective (i) when
          given personally, (ii) on the third (3rd) Business Day after being mailed by first-class registered or certified mail, postage prepaid, (iii) upon actual receipt if given by facsimile or electronic mail and such receipt is confirmed in writing by
          the recipient, or (iv) on the first Business Day following delivery to a reliable overnight courier service, courier fee prepaid, in any case at such address as may have been furnished to the Company or Holder, as the case may be, in writing by
          the Company or such Holder from time to time in accordance with the provisions of this Section 5.5.  All notices to Holder shall be addressed as follows
          until the Company receives notice of a change of address in connection with a transfer or otherwise:

      

      [_______________________

      Attn: __________________

      _______________________

        Telephone:______________

        Facsimile:_______________

        Email:__________________]

       

      Notice to the Company shall be addressed as follows until Holder receives notice of a change in address:

       

      Castle Biosciences, Inc.

          820 South Friendswood Drive, Suite 201

          Friendswood, Texas 77546

          Attn: Frank Stokes

      

       

      With a copy (which shall not constitute notice) to:

       

      Cooley LLP

          101 California Street, 5th Floor

          San Francisco, California 94111

          Attn: Maricel Mojares-Moore

          Telephone:

          Facsimile: 

          

      

      5.6          Waiver. This Warrant and any term hereof may be changed, waived, discharged or terminated (either generally or in a particular instance and either
          retroactively or prospectively) only by an instrument in writing signed by the party against which enforcement of such change, waiver, discharge or termination is sought.

       

      5.7          Attorneys’ Fees. In the event of any dispute between the parties concerning the terms and provisions of this Warrant, the party prevailing in such
          dispute shall be entitled to collect from the other party all costs incurred in such dispute, including reasonable attorneys’ fees.

       

      5.8        Counterparts; Facsimile/Electronic Signatures. This Warrant may be executed in counterparts, all of which together shall constitute one and the same
          agreement. Any signature page delivered electronically or by facsimile shall be binding to the same extent as an original signature page with regards to any agreement subject to the terms hereof or any amendment thereto.

       

      5.9           Governing Law. This Warrant shall be governed by and construed in accordance with the laws of the State of California, without giving effect to its
          principles regarding conflicts of law.

       

      5.10          Headings. The headings in this Warrant are for purposes of reference only and shall not limit or otherwise affect the meaning of any provision of this
          Warrant.

       

      5.11          Business Days. “Business Day” is any day
          that is not a Saturday, Sunday or a day on which [________________] is closed.

       

      [Remainder of page left blank intentionally]

       

      [Signature page follows]

      
        8

        
          
 

      

      IN WITNESS WHEREOF, the parties have caused this Warrant to Purchase Stock to be executed by their duly authorized representatives
        effective as of the Issue Date written above.

      
        

        

        	
                “COMPANY”

              	 
	 	 	 
	
                CASTLE BIOSCIENCES, INC.

              	 
	 	 	 
	
                By:

              	 	 
	 	 	 
	
                Name:

              	 	 
	 	
                (Print)

              	 
	
                Title:

              	 	 

        

        

        	
                “HOLDER”

              	 
	 	 	 
	
                [________________]

              	 
	 	 	 
	
                By:

              	 	 
	 	 	 
	
                Name:

              	 	 
	 	
                (Print)

              	 
	
                Title:

              	 	 

        

        

        [Signature Page to Warrant to Purchase Stock]

        

        
          
            
 

        

      

      APPENDIX 1

       

      NOTICE OF EXERCISE

       

      1.          The
          undersigned Holder hereby exercises its right purchase __________________ shares of the Common/Series ______ Preferred [circle one] Stock of CASTLE BIOSCIENCES, INC. (the “Company”) in accordance with the attached Warrant To Purchase Stock, and tenders payment of the aggregate Warrant Price for such shares as follows:

       

      
        		[     ]	
                check in the amount of $________ payable to order of the Company enclosed herewith

              

      

       

      
        		[     ]	
                Wire transfer of immediately available funds to the Company’s account

              

      

       

      
        		[     ]	
                Cashless Exercise pursuant to Section 1.2 of the Warrant

              

      

       

      
        		[     ]	
                Other [Describe] __________________________________________

              

      

       

      
        		
                2.

              	
                Please issue a certificate or certificates representing the Shares in the name specified below:

              

      

      
        	 	 	 
	 	
                Holder’s Name (Address)

              	 
	 	 	 
	 	 	 
	 	 	 
	 	
                (Address)

              	 

         

      3.          By its execution below and
          for the benefit of the Company, Holder hereby restates each of the representations and warranties in Section 4 of the Warrant to Purchase Stock as of the date hereof.

      

        	 	
                HOLDER:

              
	 	 	 	 
	 	 	 	 
	 	
                By:

              	 	 
	 	 	 	 
	 	
                Name:

              	 
	 	 	 	 
	 	
                Title:

              	 
	 	 	 	 
	 	
                Date:

              	 

      

    

    
      
        
 

    

    
      [APPENDIX 2]

       

      ASSIGNMENT

       

      For value received, [________________] hereby sells, assigns and transfers unto

      

      

      	 	
              Name:

            	
              [[______] TRANSFEREE]

            	 
	 	 	 	 
	 	
              Address:

            	 	 
	 	 	 	 
	 	
              Tax ID:

            	 	
              ]

            

      

      that certain Warrant to Purchase Stock issued by CASTLE BIOSCIENCES, INC. (the “Company”), on [_____________] (the “Warrant”) together with all rights, title and interest
        therein.

      	 	 	 	 
	 	
              [_____________]

            
	 	 	 	 
	 	
              By:

            	 	 
	 	 	 	 
	 	
              Name:

            	 
	 	 	 	 
	 	
              Title:

            	 

      

      

      	
              Date:

            	 	 

       
      By its execution below, and for the benefit of the Company, [[______] TRANSFEREE] makes each of the representations and warranties set forth in Article 4
        of the Warrant and agrees to all other provisions of the Warrant as of the date hereof.

      
        	 	 	 	 
	 	
                [[______] TRANSFEREE]

              
	 	 	 	 
	 	
                By:

              	 	 
	 	 	 	 
	 	
                Name:

              	 
	 	 	 	 
	 	
                Title:

              	 ]Exhibit 4.8

   

  THE SECURITIES REPRESENTED BY THIS INSTRUMENT HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR QUALIFIED UNDER APPLICABLE STATE SECURITIES LAWS AND HAVE BEEN TAKEN FOR INVESTMENT PURPOSES ONLY AND
    NOT WITH A VIEW TO OR FOR SALE IN CONNECTION WITH ANY DISTRIBUTION THEREOF. THE SECURITIES MAY NOT BE SOLD OR OTHERWISE TRANSFERRED IN THE ABSENCE OF SUCH REGISTRATION AND QUALIFICATION WITHOUT, EXCEPT UNDER CERTAIN SPECIFIC LIMITED CIRCUMSTANCES, AN
    OPINION OF COUNSEL FOR THE HOLDER OF THIS WARRANT, CONCURRED IN BY COUNSEL FOR THE COMPANY THAT SUCH REGISTRATION AND QUALIFICATION ARE NOT REQUIRED.

   

  [_______________]

   

  WARRANT

  

  

  TO PURCHASE SHARES OF SERIES F PREFERRED STOCK OF

  

  

  CASTLE BIOSCIENCES, INC.

   

  THIS CERTIFIES that, for value received, [__________] (the “Investor”), is entitled, upon the terms and subject to the conditions hereinafter set forth, at any time on or after the date set forth in Section 2 below and on or prior to the
    close of business on the fifth (5th) anniversary of the date hereof (the “Expiration Date”), but not thereafter, to subscribe for and purchase, from CASTLE BIOSCIENCES, INC., a
    Delaware corporation (the “Company”), [_______] shares of the Company’s Series F Preferred Stock (the “Shares”) at a purchase price of $[____] per share (the “Exercise Price”).  The Exercise Price and the number of Shares for which this Warrant is exercisable shall be subject to adjustment as provided herein.  This Warrant is one of the
    Warrants issued pursuant to that certain Second Series F Preferred Stock and Warrant Purchase Agreement of even date herewith by and among the Company and the Investors (as defined therein) (as may be amended from time to time, the ‘‘Purchase Agreement”).

   

  Immediately prior to the closing of the Company’s initial public offering of its Common Stock (the “IPO”), this warrant shall become exercisable for that number of shares of the Company’s Common Stock into which the Shares would then be convertible,
    so long as the Shares, if this warrant has been exercised prior to such offering, would have been converted into shares of the Company’s Common Stock pursuant to the automatic conversion provisions (or otherwise) of the Company’s Seventh Amended and
    Restated Certificate of Incorporation (as the same may be amended from time to time).

   

  1.          Title of Warrant.  Prior to the expiration hereof and subject to compliance with applicable laws, this Warrant and all rights hereunder are transferable, in
      whole or in part, at the office or agency of the Company, referred to in Section 2 hereof, by the registered holder of this Warrant (the “Holder”) in person or by duly authorized attorney, upon surrender of this Warrant together with the Assignment Form annexed hereto properly endorsed; provided that, if not already a party thereto, the transferee will agree in writing to be subject to the terms of the applicable Agreements (as defined in the Purchase Agreement) upon the
      acquisition of any Shares pursuant to the exercise of this Warrant.

  
    
      
 

  

  
  2.         Exercise of Warrant.

   

  (a)          The purchase
      rights represented by this Warrant are exercisable by the Holder, in whole or in part, at any time after the Closing (as defined in Purchase Agreement) and before close of business on the Expiration Date, by the surrender of the following to the
      Company at its office located in Friendswood, Texas (or such other office or agency of the Company as it may designate by notice in writing to the Holder):

   

  (i)          this Warrant;

   

  (ii)         an executed copy of the Notice of Exercise
      annexed hereto; and

   

  (iii)       payment of
      the Exercise Price (by cash or by check or bank draft payable to the order of the Company or by cancellation of indebtedness of the Company to the Holder, if any, at the time of exercise in an amount equal to the aggregate Exercise Price of the
      Shares thereby purchased).

   

  (b)          Upon the
      proper exercise of this Warrant, the Holder shall be entitled to receive a certificate for the number of Shares so purchased.  The Company agrees that if at the time of the surrender of this Warrant and purchase the Holder shall be entitled to
      exercise this Warrant, the Shares so purchased shall be and be deemed to be issued to such holder as the record owner of such Shares as of the close of business on the date on which this Warrant shall have been exercised as aforesaid.

   

  (c)          Certificates
      for the Shares purchased hereunder shall be delivered to the Holder within a reasonable time after the date on which this Warrant shall have been exercised as aforesaid.

   

  (d)          The Company
      covenants that the Shares which may be issued upon the exercise of rights represented by this Warrant will, upon exercise of the rights represented by this Warrant, be fully paid and nonassessable and free from all taxes, liens and charges in respect
      of the issue thereof.

   

  3.          Net Exercise.  Notwithstanding any provisions herein to the contrary, if the fair market value of one Share is greater than the Exercise Price (at the date
      of calculation as set forth below), in lieu of exercising this Warrant by payment as specified in Section 2(a)(iii) hereof, the Holder may elect to receive shares equal to the value (as determined below) of this Warrant (or the portion thereof being
      canceled) by surrender of this Warrant at the principal office of the Company together with the properly endorsed copy of the Notice of Exercise annexed hereto in which event the Company shall issue to the Holder a number of Shares computed using the
      following formula:

   

   X = Y (A-B)

  A

   

  Where 

   

    

  
    	

          	X =	
            the number of Shares to be issued to the Holder;

          

  

  
    -2-

    
      
 

  

  
    	

          	Y =	
            the number of Shares purchasable under this Warrant or, if only a portion of this Warrant is being exercised, the portion of this Warrant being canceled (at the date of
              such calculation)

          

  

   

  
    	

          	A =	
            the fair market value of one Share (at the date of such calculation)

          

  

   

  
    	

          	B =	
            Exercise Price (as adjusted to the date of such calculation)

          

  

   

  For purposes of the above calculation, the fair market value of one Share shall be determined by the Company’s Board of Directors in good
    faith; provided, however, that in the event that this Warrant is exercised pursuant to this Section 3 in connection with the IPO, the fair
    market value per share shall be the product of (i) the per share offering price to the public of the IPO, and (ii) the number of shares of the Company’s Common Stock into which each Share is convertible at the time of such exercise.

   

  4.          No Fractional Shares or Scrip.  No fractional shares or scrip representing fractional shares shall be issued upon the exercise of this Warrant.  With
      respect to any fraction of a Share called for upon the exercise of this Warrant, an amount equal to such fraction multiplied by the Exercise Price shall be paid in cash to the Holder.

   

  5.          Charges, Taxes and Expenses. Issuance of certificates for the Shares issued upon the exercise of this Warrant shall be made without charge to the Holder for
      any issue or transfer tax or other incidental expense in respect of the issuance of such certificate, all of which taxes and expenses shall be paid by the Company, and such certificates shall be issued in the name of the Holder or in such name or
      names as may be directed by the Holder; provided, however, that in the event certificates for such Shares are to be issued in a name other
      than the name of the Holder, this Warrant when surrendered for exercise shall be accompanied by the Assignment Form attached hereto duly executed by the Holder; and provided further, that upon any transfer involved in the issuance or delivery of any
      certificates for the Shares, the Company may require, as a condition thereto, the payment of a sum sufficient to reimburse it for any transfer tax incidental thereto.

   

  6.          No Rights as Stockholders.  This Warrant does not entitle the Holder to any voting rights or other rights as a stockholder of the Company prior to the
      exercise thereof.

   

  7.          Exchange and Registry of Warrant.  This Warrant is exchangeable, upon the surrender hereof by the Holder at the above-mentioned office or agency of the
      Company, for a new Warrant of like tenor and dated as of such exchange.

   

  The Company shall maintain at the above-mentioned office or agency a registry showing the name and address of the Holder.  This Warrant may
    be surrendered for exchange, transfer or exercise, in accordance with its terms, at such office or agency of the Company, and the Company shall be entitled to rely in all respects, prior to written notice to the contrary, upon such registry.

   

  8.          Loss, Theft, Destruction or Mutilation of Warrant.  Upon receipt by the Company of evidence reasonably satisfactory to it of the loss, theft, destruction or
      mutilation of this Warrant, and in case of loss, theft or destruction, of indemnity or security reasonably satisfactory to it, and upon reimbursement to the Company of all reasonable expenses incidental thereto, and upon surrender and cancellation of
      this Warrant, if mutilated, the Company will make and deliver a new Warrant of like tenor and dated as of such cancellation, in lieu of this Warrant.

  
    -3-

    
      
 

  

  9.           Saturdays, Sundays, Holidays, etc.  If the last or appointed day for the taking of any action or the expiration of any right required or granted herein
      shall be a Saturday or a Sunday or shall be a legal holiday, then such action may be taken or such right may be exercised on the next succeeding day not a legal holiday.

   

  10.          Early Termination and Dilution.

   

  (a)          Merger, Sale of Assets, etc.  If at any time the Company proposes to (i) consolidate with merge with, sell or convey all or substantially all of its assets
      to any other corporation, or effect some other form of reorganization, or (ii) effect a registered public offering of its shares, then the Company shall give the Holder thirty (30) days notice of the proposed effective date of such transaction and if
      this Warrant has not been exercised by the effective date of such transaction this Warrant shall terminate.

   

  (b)          Reclassification, etc.  If the Company at any time shall, by subdivision, combination or reclassification of securities or otherwise, change any of the
      securities to which purchase rights under this Warrant exist into the same or a different number of securities of any class or classes, this Warrant shall thereafter be to acquire such number and kind of securities as would have been issuable as the
      result of such change with respect to the securities which were subject to the purchase rights under this Warrant immediately prior to such subdivision, combination, reclassification or other change.  If shares of the Company’s Series F Preferred
      Stock (the “Series F Preferred”) are subdivided or combined into a greater or smaller number of shares of the Series F
      Preferred, the Exercise Price shall be proportionately reduced in case of subdivision of shares or proportionately increased in the case of combination of shares, in both cases by the ratio which the total number of shares of Series F Preferred to be
      outstanding immediately after such event bears to the total number of shares of Series F Preferred outstanding immediately prior to such event.

   

  (c)          Cash Distributions.  No adjustment on account of cash dividends or interest on the Shares or other securities purchasable hereunder will be made to the
      Exercise Price.

   

  (d)          Authorized Shares.  The Company covenants that during the period in which this Warrant is outstanding and exercisable, it will reserve from its authorized
      and unissued Series F Preferred a sufficient number of shares to provide for the issuance of the Shares.  The Company further covenants that its issuance of this Warrant shall constitute full authority to its officers who are charged with the duty of
      executing stock certificates to execute and issue the necessary certificates for the Shares.

   

  11.          Miscellaneous.

   

  (a)          Issue Date.  The provisions of this Warrant shall be construed and shall be given effect in all respects as if it had been issued and delivered by the
      Company on the date hereof.  This Warrant shall be binding upon any successors or assigns of the Company.  This Warrant shall be governed by and construed under the laws of the State of Delaware, without regard to the conflicts of laws provisions
      thereof.

  
    -4-

    
      
 

  

  (b)          Restrictions.  The Holder acknowledges that the Shares may be subject to transfer and sale restrictions imposed by state and federal securities laws or
      pursuant to Company agreements.  The Holder understands and agrees that all certificates evidencing the shares of stock issuable hereunder may bear the following legend:

   

  “THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED
    (THE “ACT”), OR UNDER THE SECURITIES LAWS OF CERTAIN STATES.  THESE SECURITIES MAY NOT BE OFFERED, SOLD, OR OTHERWISE TRANSFERRED,
    PLEDGED OR HYPOTHECATED EXCEPT AS PERMITTED UNDER THE ACT AND APPLICABLE STATE SECURITIES LAWS PURSUANT TO REGISTRATION OR AN EXEMPTION THEREFORM.  THE ISSUER OF THESE SECURITIES MAY REQUIRE AN OPINION OF COUNSEL REASONABLY SATISFACTORY TO THE ISSUER
    THAT SUCH OFFER, SALE OR TRANSFER, PLEDGE OR HYPOTHECATION OTHERWISE COMPLIES WITH THE ACT AND ANY APPLICABLE STATE SECURITIES LAWS.”

   

  (c)          Waivers and Amendments.  With the consent of the Record Holders (as defined below) holding rights to purchase more than fifty percent (50%) of the shares
      issuable upon exercise of the then outstanding Series F Warrants (as defined below), the obligations of the Company and the rights of the Record Holders may be waived (either generally or in a particular instance, either retroactively or
      prospectively and either for a specified period of time or indefinitely), and with the same consent the Company may enter into a supplementary agreement for the purpose of adding any provisions to or changing in any manner or eliminating any of the
      provisions of the Warrants; provided, however, that no such waiver or supplemental agreement shall reduce the aforesaid percentage which is required for consent to any waiver or supplemental agreement, without the consent of all of the Record Holders
      of the then outstanding Warrants.  As used in this paragraph 10(c), (i) “Series F Warrants” shall mean the “Series F Warrants” as issued pursuant to and defined in the Purchase Agreement, and (ii) the “Record Holders” shall be the record holders of
      all outstanding Warrants.

   

  (d)          Market Stand-Off Agreement.  The Holder shall not sell, dispose of, transfer, make any short sale of, grant any option for the purchase of, or
      enter into any hedging or similar transaction with the same economic effect as a sale, any Shares (or other securities) held by such Holder, for a period of time specified by the representative of the underwriters of the Company’s Common Stock (or
      other securities) not to exceed 180 days following the effective date of a registration statement of the Company filed under the Act (or such longer period as necessary to permit compliance with NASD Rule 2711 or NYSE Member Rule 472 and similar or
      successor regulatory rules and regulations).  The Holder agrees to execute and deliver such other agreements as may be reasonably requested by the Company and/or the managing underwriter(s) which are consistent with the foregoing or which are
      necessary to give further effect thereto.  In order to enforce the foregoing covenant, the Company may impose stop-transfer instructions with respect to the Shares (or other securities) held by such Holder until the end of such period.  The
      underwriters of the Company’s stock are intended third party beneficiaries of this Section 10(d) and shall have the right, power and authority to enforce the provisions hereof as though they were a party hereto.

  
    -5-

    
      
 

  

  IN WITNESS WHEREOF, CASTLE BIOSCIENCES, INC, has caused this Stock Purchase Warrant to be executed by its officer thereunto duly authorized
    as of the date first set forth above,

   

  
    	
             

          	
            CASTLE BIOSCIENCES, INC.

          
	
             

          	
             

          	
             

          
	
             

          	
            By 

          	
             

          
	
             

          	
             

          	
             

          
	 	Name: 
	 	
            Title:

          

    

    

    
      	
              AGREED AND ACKNOWLEDGED:

            	 
	 	 	 
	
              [________________]

            	 
	 	 	 
	
              By:

            	 	 
	 	 	 
	
              Name:

            	 	 
	 	

            	 
	
              Title:

            	 	 
	 	 	 
	Address: 	 

      

      

      
        Castle Biosciences, Inc.

        Signature Page To Warrant To Purchase Series F Preferred Stock

        
          
            
 

        

      

    

  

  NOTICE OF EXERCISE

   

  To:          CASTLE BIOSCIENCES, INC.

   

  (1)          The
      undersigned hereby elects to purchase _________ shares of Series F Preferred Stock of CASTLE BIOSCIENCES, INC. pursuant to the terms of the attached Warrant, and tenders herewith payment of the aggregate purchase price of such shares of Series F
      Preferred Stock in full, together with all applicable transfer taxes, if any.

   

  (2)          Please issue a certificate of
      certificates representing said shares of Series F Preferred Stock in the name of the undersigned or in such other name as is specified below:

   

   

  

   

  

  
    	
             

          	
             (Name)

          	
             

          
	
             

          	
             

          	
             

          
	
             

          	
             

          	
             

          
	
             

          	
             (Address)

          	
             

          

  

  

  (3)          The
      undersigned represents that the aforesaid shares of Series F Preferred Stock are being acquired for the account of the undersigned for investment and not with a view to, or for resale in connection with, the distribution thereof and that the
      undersigned has no present intention of distributing or reselling such shares.

  
    	 	 	 
	
            [________________]

          	 
	 	 	 
	
            By:

          	 	 
	 	 	 
	
            Name:

          	 	 
	 	

          	 
	
            Title:

          	 	 
	 	 	 
	Date:	 	 

  

  
    
      
 

  

  
    ASSIGNMENT FORM

     

    (To assign the foregoing warrant, execute this form and supply required information. Do not use this form to purchase shares.)

     

    FOR VALUE RECEIVED, the foregoing Warrant and all rights evidenced thereby are hereby assigned to

     

     

    

    
      	
              (Please Print)

            

    

    

    

    
      	
              whose address is

            	
               

            

    

    
      (Please Print)

       

    

    
      	
               

            

    

    

    Dated: __________________________________ , 20__

     

    
      	
               

            	
              Holder’s Signature:

            	
               

            
	 	 	 
	 	Holder’s Address:	 
	 	 	 
	 	 	 

    

    

    

    
      	
              Signature Guaranteed:

            	
               

            

    

  

   
    NOTE:  The signature to this Assignment Form must correspond with the name as it appears on the face of the Warrant, without alteration or enlargement or any
      change whatever, and must be guaranteed by a bank or trust company. Officers of corporations and those acting in a fiduciary or other representative capacity should file proper evidence of authority to assign the foregoing Warrant.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00297-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00297-of-00352.parquet"}]]